Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
Status:
Withdrawn
Trial end date:
2025-02-19
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed
diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate
the incidence of ITP remission.